ATE228361T1 - Reduzierung der kardiotoxizität von antitumormitteln mit manganverbindungen - Google Patents

Reduzierung der kardiotoxizität von antitumormitteln mit manganverbindungen

Info

Publication number
ATE228361T1
ATE228361T1 AT97928368T AT97928368T ATE228361T1 AT E228361 T1 ATE228361 T1 AT E228361T1 AT 97928368 T AT97928368 T AT 97928368T AT 97928368 T AT97928368 T AT 97928368T AT E228361 T1 ATE228361 T1 AT E228361T1
Authority
AT
Austria
Prior art keywords
reducing
compounds
cardiotoxicity
manganeous
antitumor drugs
Prior art date
Application number
AT97928368T
Other languages
German (de)
English (en)
Inventor
Robertson Towart
Jan Olof Gustav Karlsson
Per Jynge
Original Assignee
Amersham Health As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amersham Health As filed Critical Amersham Health As
Application granted granted Critical
Publication of ATE228361T1 publication Critical patent/ATE228361T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/32Manganese; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/04Chelating agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Semiconductor Lasers (AREA)
  • Manufacture And Refinement Of Metals (AREA)
AT97928368T 1996-06-24 1997-06-24 Reduzierung der kardiotoxizität von antitumormitteln mit manganverbindungen ATE228361T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9613182.6A GB9613182D0 (en) 1996-06-24 1996-06-24 Method
PCT/GB1997/001721 WO1997049390A1 (en) 1996-06-24 1997-06-24 Reduction of cardiotoxicity of an antitumor agent using manganese compound

Publications (1)

Publication Number Publication Date
ATE228361T1 true ATE228361T1 (de) 2002-12-15

Family

ID=10795775

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97928368T ATE228361T1 (de) 1996-06-24 1997-06-24 Reduzierung der kardiotoxizität von antitumormitteln mit manganverbindungen
AT97928369T ATE225178T1 (de) 1996-06-24 1997-06-24 Chelate und metalchelate zur behandlung von durch freie radikale verursachte zustände

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97928369T ATE225178T1 (de) 1996-06-24 1997-06-24 Chelate und metalchelate zur behandlung von durch freie radikale verursachte zustände

Country Status (14)

Country Link
US (2) US6147094A (https=)
EP (2) EP0936915B1 (https=)
JP (2) JP4359651B2 (https=)
CN (2) CN1228694A (https=)
AT (2) ATE228361T1 (https=)
AU (2) AU720621B2 (https=)
BR (1) BR9709942A (https=)
CA (2) CA2258299A1 (https=)
DE (2) DE69717447T2 (https=)
GB (1) GB9613182D0 (https=)
IL (1) IL127733A0 (https=)
NO (2) NO985916L (https=)
NZ (2) NZ333357A (https=)
WO (2) WO1997049409A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727224D0 (en) * 1997-12-23 1998-02-25 Nycomed Imaging As Method
AU1770299A (en) * 1997-12-23 1999-07-19 Nycomed Imaging As Nitric oxide releasing chelating agents and their therapeutic use
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
CN1390231A (zh) 1999-10-01 2003-01-08 Dmi生物科学公司 金属-结合性化合物及其用途
FR2823977B1 (fr) * 2001-04-26 2006-12-01 Univ Rene Descartes Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US20040038904A1 (en) * 2002-05-21 2004-02-26 Angela Ogden Method of treating multiple sclerosis
FR2863892B1 (fr) * 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
EP2407169A1 (en) 2004-04-22 2012-01-18 Celator Pharmaceuticals, Inc. Combination formulations of anthracycline agents and cytidine analogs
LT3311805T (lt) 2005-08-31 2020-04-27 Abraxis Bioscience, Llc Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus
KR101678865B1 (ko) * 2007-12-14 2016-11-23 플레드파르마 에이비 암의 치료에 사용하기 위한 화합물들
CN105688215A (zh) * 2009-07-06 2016-06-22 普莱制药公司 利用锰配合物化合物与所述化合物之非锰配合物形式的组合的药物组合物和治疗方法
AU2012253571A1 (en) 2011-05-09 2014-01-09 Mayo Foundation For Medical Education And Research Cancer treatments
CN107353313B (zh) 2012-01-05 2019-04-09 普莱制药公司 新化学实体钙锰福地吡和其他混合金属配合物、制备方法、组合物以及治疗方法
US10413606B2 (en) 2012-10-01 2019-09-17 Mayo Foundation For Medical Education And Research Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
MX376321B (es) 2012-11-02 2025-03-07 Egetis Therapeutics Ab Usos para el tratamiento de cancer.
EP3154586B1 (en) 2014-06-13 2020-05-27 Mayo Foundation for Medical Education and Research Treating lymphomas
KR20170020371A (ko) 2014-06-16 2017-02-22 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 골수종의 치료
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體-抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
WO2017139698A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
EP3432928A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
EP3432926A4 (en) * 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research METHOD FOR REDUCING THE TOXICITY OF CHEMOTHERAPEUTICS
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
JP2019526579A (ja) 2016-09-01 2019-09-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチMayo Foundation For Medical Education And Research T細胞癌を標的とする為の方法及び組成物
WO2018045239A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Carrier-pd-l1 binding agent compositions for treating cancers
EP3509635A1 (en) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
RU2021128415A (ru) 2016-09-06 2021-11-08 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения
KR20230011473A (ko) 2016-09-06 2023-01-20 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Pd-l1 발현 암의 치료 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES444380A1 (es) * 1976-01-16 1977-06-16 Gosalvez Mario Un procedimiento para preparar derivados metalicos antraci- clinicos.
US4842845A (en) * 1987-05-08 1989-06-27 Salutar, Inc. Radioactive metal chelates for dipyridoxyl phosphate
US5223243A (en) * 1987-05-08 1993-06-29 Salutar, Inc. Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents
US4935518A (en) * 1987-05-08 1990-06-19 Salutar, Inc. Manganese(II), chelate contrast agents derived from N,N'-bis-(pyridoxal ethylene diamine-N,N')-diacetic acid and derivatives thereof
US6204259B1 (en) * 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide

Also Published As

Publication number Publication date
AU3268897A (en) 1998-01-14
AU720570B2 (en) 2000-06-08
NZ333315A (en) 2000-07-28
DE69717447T2 (de) 2003-09-11
DE69716104T2 (de) 2003-05-28
JP2000514044A (ja) 2000-10-24
JP4359651B2 (ja) 2009-11-04
NO985917L (no) 1999-01-25
CN1228703A (zh) 1999-09-15
DE69716104D1 (de) 2002-11-07
EP0936915A1 (en) 1999-08-25
DE69717447D1 (de) 2003-01-09
AU720621B2 (en) 2000-06-08
NO985916L (no) 1999-01-25
WO1997049409A1 (en) 1997-12-31
NZ333357A (en) 2000-08-25
IL127733A0 (en) 1999-10-28
EP0910360A1 (en) 1999-04-28
BR9709942A (pt) 1999-08-10
US6258828B1 (en) 2001-07-10
CA2259150A1 (en) 1997-12-31
AU3268997A (en) 1998-01-14
EP0910360B1 (en) 2002-11-27
JP4162263B2 (ja) 2008-10-08
CN1228694A (zh) 1999-09-15
EP0936915B1 (en) 2002-10-02
US6147094A (en) 2000-11-14
JP2000513351A (ja) 2000-10-10
NO985916D0 (no) 1998-12-17
GB9613182D0 (en) 1996-08-28
ATE225178T1 (de) 2002-10-15
CA2258299A1 (en) 1997-12-31
WO1997049390A1 (en) 1997-12-31
NO985917D0 (no) 1998-12-17

Similar Documents

Publication Publication Date Title
ATE228361T1 (de) Reduzierung der kardiotoxizität von antitumormitteln mit manganverbindungen
DE69703294D1 (de) Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten
PT960107E (pt) Compostos de paclitaxel 6-tio-substituidos
DE69708100D1 (de) Konjugate von cis-docosahexaensäure und paclitaxel
DZ2614A1 (fr) Compositions pharmaceutiques topiques contenant des dérivés de résorcinol.
ES2181744T3 (es) Hidratos de paclitaxel cristalinos.
BR9912327A (pt) Inibidores da uroquinase
PT1109571E (pt) Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos
MX9601994A (es) Profarmacos de derivados de paclitaxel.
DE69907926D1 (de) 1,2,4-triazol-3-thion verbindungen
WO1996041627A3 (en) Iron compounds, compositions, methods of making the same and uses thereof
MXPA02005045A (es) Preparaciones farmaceuticas que contiene agentes citostaticos y aceptores de electrones para el tratamiento de cancer.
AU8851298A (en) L-threonate ferrous, as well as pharmaceutical composition and use for improvingand treating human anemia thereof
DE69512715D1 (de) Aconitin ähnliche verbindung und antipyretisches, analgetisches und entzündungshemmendes mittel
DK1135169T3 (da) Anvendelse af et farmaceutisk præparat indeholdende et anticancermiddel og mindst et peptid.
DE69818492D1 (en) 7-methylthiooxomethyl- und 7-methylthiodioxomethyl-paclitaxele
DK0777498T3 (da) Konjugater fremstillet af metalkomplekser og oligonucleotider
EA200100353A1 (ru) Применение производного антрациклина для лечения опухоли печени
WO2002038566A3 (en) Carbene porphyrins and carbene porphyrinoids for use in medical diagnosis and treatment
WO2001000189A3 (de) Kombination von mtp-inhibitoren und stoffwechselbeeinflussenden wirkstoffen und ihre verwendung in arzneimitteln
ES2195922T3 (es) Composicion sinergica que comprende derivados de daunorrubicina y compuestos antimetabolitos.
RU95118900A (ru) Противоопухолевое средство

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties